Niemann-Pick disease, sometimes called Classical Niemann-Pick Disease, DAF syndrome, lipoid histiocytosis (classical phosphatide), Neuronal Cholesterol Lipidosis, NPD, Ophthalmoplegia, Supraoptic Vertical, Sphingomyelinase deficiency, Sphingomyelin/cholesterol lipidosis, or Sphingomyelin lipidosis, is an inherited condition that leads to abnormal lipid metabolism that causes harmful amounts of lipids to accumulate in the spleen, liver, lungs, bone marrow, and brain. Types A, B, and C of Niemann-Pick disease exist, characterized by the genetic cause and signs and symptoms and depending on the type of Niemann-Pick disease contracted and the onset varies from infancy to adulthood. Mutations in the NPC1, NPC2, and SMPD1 genes cause Niemann-Pick disease and this condition is inherited in an autosomal recessive pattern. The incidence of Niemann-Pick disease type A and B is 1 in 250,000 and type C is 1 in 150,000 in all populations other than eastern and central Europeans, where it is 1 in 40,000. Approximately 85% of Niemann-Pick disease type A cases result in fatality by the age of 18 months, while most cases of types B and C result in patients living into teens or adulthood. There is no cure for Niemann-Pick disease but only measures such as lower cholesterol levels, some experimental drugs, and the treatment of symptoms.
Niemann-pick Diseases Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Niemann-pick Diseases below!
For more information on how to use Laverne, please read the How to Guide.
We have 2516 products for the study of Niemann-pick Diseases that can be applied to Chromatin Immunoprecipitation, Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Niemann-pick Diseases is also known as Niemann Pick Disease, Niemann-pick Disease.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.